Nivolumab

• A Phase 3 Study of Nivolumab versus Placebo for Participants with Hepatocellular Cancer Who Are at High Risk of Recurrence after Hepatic Res… Ended
  2023-508726-10-00 Phase III 8 countries Bristol-Myers Squibb Services Unlimited Company
• Phase I-II trial of sunitinib and/or nivolumab plus chemotherapy in advanced soft tissue and bone sarcomas Ended
  2024-514776-40-00 Phase I/II 2 countries Asoc Grupo Espanol De Investigacion En Sarcomas
• Adaptive phase II randomized non-comparative trial of nivolumab after induction treatment in triple-negative breast cancer (TNBC) patients: … Ended
  2025-520487-18-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study Ended
  2023-503803-27-00 Phase III 8 countries Janssen - Cilag International
• A phase II trial to study the effectivity of combination immunotherapy in patients with prostate cancer (INSPIRE) Ended
  2024-513186-39-01 Phase II 1 country Stichting Radboud universitair medisch centrum
• A Phase 1/2 Study of BMS-986408 with and without Nivolumab or Nivolumab and Ipilimumab in Participants with Solid Tumors Ended
  2022-500823-61-00 Phase I (FiH) 2 countries Bristol-Myers Squibb International Corporation
• Phase 1/2 Study of BDC-1001 as a Single Agent and in Combination with Nivolumab in Patients with Advanced HER2-Expressing Solid Tumors Ended
  2024-518411-19-00 Phase I/II 1 country Bolt Biotherapeutics Inc.
• A Phase 1b/2 Study of BMS-986442 with Nivolumab with or without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer Ended
  2022-503108-26-00 Phase I (FiH) 3 countries Bristol-Myers Squibb Services Unlimited Company
• Phase 2 Study of Encorafenib and Binimetinib Plus Pembrolizumab in Participants With BRAF V600E/K Mutation-Positive Melanoma Who Progressed … Ended
  2023-509471-17-00 Phase II 5 countries Pfizer Inc.
• A clinical trial to investigate EO4010, a novel cancer vaccine therapy, with an immune checkpoint blocker, in patients with previously treat… Ended
  2023-509509-62-00 Phase I (FiH) 2 countries Enterome
• Relatlimab + Nivolumab in Pediatric and Young Adult Lymphomas (RELATIVITY-069) Ended
  2023-503715-14-00 Phase I/II 4 countries Bristol Myers Squibb International Corporation
• A first-in-human clinical trial in adult patients with metastatic or recurrent melanoma of a personalised therapy targeting specific mutatio… Ended
  2024-513062-19-00 Phase I (FiH) 1 country Achilles Therapeutics UK Limited
• A PHASE 1/2 STUDY OF ONCOBAX®-AK ADMINISTERED IN COMBINATION WITH IMMUNOTHERAPY TO PATIENTS WITH ADVANCED SOLID TUMORS Ended
  2024-516711-24-00 Phase I (FiH) 2 countries Everimmune
• Nivolumab during active surveillance after neoadjuvant chemoradiation for esophageal cancer: SANO-3 study Ended
  2024-513635-24-00 Phase II/III 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
• Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102) Ended
  2023-505458-16-00 Phase III 12 countries Amgen Inc.
• Phase 1/2 study of Nivolumab and Relatlimab in Combination with Bevacizumab in First-line HCC Ended
  2024-510649-33-00 Phase I/II 5 countries Bristol Myers Squibb International Corporation
• Phase II non randomized clinical trial of NIVOLUMAB/IPILIMUMAB maintenance following first-line chemotherapy in unresectable locally advance… Ended
  2024-514293-46-00 Phase II 1 country Grupo Espanol De Oncologia Genitourinaria-Socug
• Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma (CLAUDIO-01) Ended
  2023-504441-31-00 Phase I (FiH) 4 countries SOTIO Biotech a.s.
• Phase II Study of Fedratinib and Nivolumab Combination in Patients with Myelofibrosis and Resistance or Suboptimal Response to JAK-inhibitor… Ended
  2024-513953-64-00 Phase II 1 country Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
• RegoNivo vs Standard of Care Chemotherapy in AGOC (INTEGRATEIIb) Ended
  2023-505441-69-00 Phase III 4 countries Institut fuer Klinische Krebsforschung IKF GmbH
• An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers Ended
  2023-508954-25-00 Phase I (FiH) 3 countries Bristol Myers Squibb International Corporation
• Neoadjuvant Nivolumab and chemotherapy in stage I-II triple negative breast cancer. Ended
  2024-512625-86-00 Phase II 1 country ANZ Breast Cancer Trials Group Limited
• Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Ended
  2024-514570-43-00 Phase III 8 countries Aveo Pharmaceuticals Inc.
• Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III… Ended
  2023-507688-20-00 Phase III 13 countries Bristol Myers Squibb International Corporation

Showing 145–168 of 206 trials